Lassen FH, Venkatesh SS, Baya N, et al. Exome-wide evidence of compound heterozygous effects across common phenotypes in the UK Biobank. Cell genomics. 2024:100602. doi:10.1016/j.xgen.2024.100602
Publications
Scott-Hewitt N, Mahoney M, Huang Y, et al. Microglial-derived C1q integrates into neuronal ribonucleoprotein complexes and impacts protein homeostasis in the aging brain. Cell. 2024. doi:10.1016/j.cell.2024.05.058
Trsan T, Peng V, Krishna C, et al. The centrosomal protein FGFR1OP controls myosin function in murine intestinal epithelial cells. Developmental cell. 2024. doi:10.1016/j.devcel.2024.06.001
Bellomo TR, Liu Y, Gilliland TC, et al. Associations between lipoprotein(a), oxidized phospholipids, and extra-coronary vascular disease. Journal of lipid research. 2024:100585. doi:10.1016/j.jlr.2024.100585
Liu J, Richmond RC, Anderson EL, et al. The role of accelerometer-derived sleep traits on glycated haemoglobin and glucose levels: a Mendelian randomization study. Scientific reports. 2024;14(1):14962. doi:10.1038/s41598-024-58007-9
Scott-Hewitt N, Mahoney M, Huang Y, et al. Microglial-derived C1q integrates into neuronal ribonucleoprotein complexes and impacts protein homeostasis in the aging brain. Cell. 2024. doi:10.1016/j.cell.2024.05.058
Scott-Hewitt N, Mahoney M, Huang Y, et al. Microglial-derived C1q integrates into neuronal ribonucleoprotein complexes and impacts protein homeostasis in the aging brain. Cell. 2024. doi:10.1016/j.cell.2024.05.058
Petros BA. Identifying changes in viral fitness using population genetic structure. Proceedings of the National Academy of Sciences of the United States of America. 2024;121(28):e2410274121. doi:10.1073/pnas.2410274121
Debban CL, Ambalavanan A, Ghosh A, et al. Dysanapsis Genetic Risk Predicts Lung Function Across the Lifespan. American journal of respiratory and critical care medicine. 2024. doi:10.1164/rccm.202401-0011OC
Gupta AA, Xue W, Harrison DJ, et al. Addition of temsirolimus to chemotherapy in children, adolescents, and young adults with intermediate-risk rhabdomyosarcoma (ARST1431): a randomised, open-label, phase 3 trial from the Children’s Oncology Group. The Lancet. Oncology. 2024;25(7):912-921. doi:10.1016/S1470-2045(24)00255-9